News & Updates

People living with HIV-1 (PLWH) who discontinued traditional non-nucleoside reverse transcriptase inhibitor (NNRTI)- and boosted integrase strand transfer inhibitor (INSTI)-based regimens have maintained viral suppression following their switch to the next-generation NNRTI ainuovirine coformulated with lamivudine and tenofovir DF (ANV/3TC/TDF), as shown by the 144-week open-label results from the SPRINT* post-study presented at ESCMID Global 2026.

An open-label extension (OLE) study demonstrates the long-term safety, tolerability, and efficacy of atogepant for migraine prevention.

Treatment with colchicine and famotidine plus loratadine, in addition to specialist supportive care, can substantially ease severe fatigue among patients suffering from long COVID, as shown by the results of the STIMULATE ICP trial.

In the treatment of patients with proliferative diabetic retinopathy, brolucizumab outperforms panretinal laser photocoagulation in terms of preserving visual acuity, according to the international phase III CONDOR trial.

Treatment with semaglutide appears effective in reducing the risk of adult-onset epilepsy or seizures relative to sodium–glucose cotransporter-2 inhibitors (SGLT2i) and other glucose-lowering drugs (GLDs) in patients with type 2 diabetes mellitus (T2DM), according to a study presented at AAN 2026.

The use of fremanezumab in children and adolescents with episodic migraine (EM) results in significant reductions in monthly migraine days (MMD) and monthly headache days (MHD), but it appears to be no better than placebo among those with chronic migraine (CM), as shown by outcomes from two randomized, phase III trials presented at AAN 2026.

Triple therapy with angiotensin receptor blockers (ARBs)/amlodipine + rosuvastatin significantly reduces blood pressure (BP) and cholesterol levels in patients with hypertension and dyslipidaemia compared with dual therapies involving ARBs/amlodipine or ARBs + rosuvastatin, according to a recent study.